Tvardi Therapeutics (LTS:0HTC) Forward Dividend Yield %: 0.00% (As of Jun. 29, 2026)


What is Tvardi Therapeutics Forward Dividend Yield %?

Tvardi Therapeutics LTS:0HTC 12 Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 145 Biotechnology companies, Tvardi Therapeutics ranks worse than 689654.48% on this metric.

As of today (2026-06-29), the Forward Annual Dividend Yield of Tvardi Therapeutics is 0.00%.

As of today (2026-06-29), the Trailing Annual Dividend Yield of Tvardi Therapeutics is 0.00%.

LTS:0HTC's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

Tvardi Therapeutics's Dividends per Share for the three months ended in Mar. 2026 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Tvardi Therapeutics  (LTS:0HTC) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Tvardi Therapeutics Forward Dividend Yield % Related Terms

LTS:0HTC vs HOWL, TPST, XCUR: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Forward Dividend Yield % falls into.


Tvardi Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Tvardi Therapeutics (LTS:0HTC) has a Forward Dividend Yield % of 0.00% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry.
Is Tvardi Therapeutics' Forward Dividend Yield % too high?
Tvardi Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Tvardi Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Forward Dividend Yield % compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Tvardi Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.51, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.